Arix Bioscience PLC has provided an update on the recommended all-share acquisition of its assets by RTW Biotech Opportunities Ltd (RTW Bio) and the publication of the Notice of Second General Meeting. The acquisition is to be effected through a scheme of reconstruction and the voluntary winding-up of Arix under section 110 of the Insolvency Act 1986. Arix has announced that the Shareholder circular containing the notice of the Second General Meeting, together with the associated form of proxy, is being sent to Shareholders and made available for inspection. The Second General Meeting is scheduled to be held on 12 February 2024 at Clifford Chance LLP, London. Shareholders are recommended to vote in favor of the Resolutions to be proposed at the General Meetings.